Standout Papers

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. 1997 2026 2006 2016 523
  1. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. (1997)
    W ten Bokkel Huinink, Martin Gore et al. Journal of Clinical Oncology

Immediate Impact

2 by Nobel laureates 8 from Science/Nature 61 standout
Sub-graph 1 of 21

Citing Papers

Transferrin receptor targeting chimeras for membrane protein degradation
2024 StandoutNature
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
2023 Standout
1 intermediate paper

Works of Anderley Gordon being referenced

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study
2005
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.
1997 Standout

Author Peers

Author Last Decade Papers Cites
Anderley Gordon 569 896 526 31 1.3k
W ten Bokkel Huinink 411 543 448 22 1.2k
Eizo Kimura 381 735 363 20 1.1k
M E van der Burg 454 669 637 18 1.4k
Ahmed Elattar 391 689 448 32 1.1k
Barbara Kulp 522 730 574 37 1.6k
Antonio Santillan 655 858 286 27 1.5k
Henric Malmström 700 1193 467 29 1.7k
Abbie L. Fields 321 451 312 42 1.2k
C. Mangioni 499 872 402 50 1.5k
I. Vergote 631 1029 365 67 1.6k

All Works

Loading papers...

Rankless by CCL
2026